(Q46852439)

English

Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial

scientific article published in January 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18077217

Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18077217

phase II clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

multicenter clinical trial

1 reference

based on heuristic

inferred from title

pancreatic cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Rossana Berardi

2

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18077217

Roberto Labianca

3

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18077217

Giuseppe Tonini

10

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18077217

Mario Scartozzi

15

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18077217

Salvatore Siena

object named as

Salvatore Siena

4

0 references

Stefano Cascinu

object named as

Stefano Cascinu

1

0 references

Alfredo Falcone

object named as

Alfredo Falcone

5

0 references

author name string

Enrico Aitini

6

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18077217

Sandro Barni

7

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18077217

Francesco Di Costanzo

8

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18077217

Elisa Dapretto

9

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18077217

Chiara Pierantoni

11

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18077217

Salvatore Artale

12

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18077217

Silvia Rota

13

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18077217

Irene Floriani

14

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18077217

Alberto Zaniboni

16

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18077217

Italian Group for the Study of Digestive Tract Cancer (GISCAD)

17

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18077217

publication date

1 January 2008

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18077217

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18077217

9

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18077217

1

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18077217

39-44

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18077217

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970383-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970383-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970383-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970383-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970383-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970383-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970383-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970383-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970383-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970383-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970383-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970383-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970383-2

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970383-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Sample size tables for exact single-stage phase II designs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970383-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970383-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970383-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970383-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II designs in cancer clinical trials: current status and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970383-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Design issues of randomized phase II trials and a proposal for phase II screening trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970383-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(07)70383-2

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18077217

release_om5xpux4vzdg5ero754tce24w4

1 reference

https://api.fatcat.wiki/v0/release/om5xpux4vzdg5ero754tce24w4

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18077217

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46852439&oldid=2138134745"